ES2074268T3 - Vacunacion idiotipica contra el linfoma de celulas b. - Google Patents

Vacunacion idiotipica contra el linfoma de celulas b.

Info

Publication number
ES2074268T3
ES2074268T3 ES91905685T ES91905685T ES2074268T3 ES 2074268 T3 ES2074268 T3 ES 2074268T3 ES 91905685 T ES91905685 T ES 91905685T ES 91905685 T ES91905685 T ES 91905685T ES 2074268 T3 ES2074268 T3 ES 2074268T3
Authority
ES
Spain
Prior art keywords
dendritic cells
idiotype
idiotipic
conformation
cell lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91905685T
Other languages
English (en)
Inventor
Heribert Bohlen
Jacques Urbain
Camp Benjamin Van
Kristiaan Thielemans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Original Assignee
Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23960532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2074268(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Response Corp filed Critical Immune Response Corp
Application granted granted Critical
Publication of ES2074268T3 publication Critical patent/ES2074268T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

LA INVENCION SUMINISTRA UN METODO DE INDUCIR UNA RESPUESTA INMUNE EFECTIVA A LOS LINFOCITOS PATOGENICOS MEDIANTE LA ADMINISTRACION DE CELULAS DENDRITICAS PREVIAMENTE IMPULSADAS CON LA PROTEINA DEL IDIOTIPO DE INTERES. EN UNA CONFORMACION, SE SUMINISTRA UN METODO PARA LA INMUNIZACION ACTIVA DE UN MAMIFERO CONTRA EL LINFOMA. ESTA CONFORMACION COMPRENDE LA EXPOSICION DE LAS CELULAS DENDRITICAS AL IDIOTIPO IG PARA CONSEGUIR CELULAS DENDRITICAS IMPULSADAS CON EL IDIOTIPO E INYECTAR LAS CELULAS DENDRITICAS IMPULSADAS CON EL IDIOTIPO DE NUEVO EN EL MAMIFERO, MEDIANTE LO CUAL SE INDUCE LA INMUNIDAD CONTRA LAS CELULAS DEL LINFOMA. EN OTRA CONFORMACION, LA INVENCION SE REFIERE A LA ADMINISTRACION TANTO DE CELULAS IDIOTIPICAS COMO DE CELULAS DENDRITICAS.
ES91905685T 1990-03-14 1991-03-13 Vacunacion idiotipica contra el linfoma de celulas b. Expired - Lifetime ES2074268T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/493,511 US20030072751A1 (en) 1990-03-14 1990-03-14 Idiotypic vaccination against b cell lymphoma

Publications (1)

Publication Number Publication Date
ES2074268T3 true ES2074268T3 (es) 1995-09-01

Family

ID=23960532

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91905685T Expired - Lifetime ES2074268T3 (es) 1990-03-14 1991-03-13 Vacunacion idiotipica contra el linfoma de celulas b.

Country Status (12)

Country Link
US (1) US20030072751A1 (es)
EP (1) EP0521897B1 (es)
JP (1) JP2735947B2 (es)
AT (1) ATE124265T1 (es)
AU (1) AU645552B2 (es)
CA (1) CA2078235C (es)
DE (1) DE69110877T2 (es)
DK (1) DK0521897T3 (es)
ES (1) ES2074268T3 (es)
FI (1) FI105452B (es)
NO (1) NO308509B1 (es)
WO (1) WO1991013632A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
DK0633929T3 (da) * 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
EP1421947A1 (en) * 1992-07-22 2004-05-26 The Trustees Of Princeton University p53 vaccine
EP0672118B1 (en) * 1992-08-21 2002-03-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A novel b-lymphoma cell line and antigen
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
AU6363094A (en) * 1993-03-15 1994-10-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Peptide coated dendritic cells as immunogens
AU710783B2 (en) * 1994-06-14 1999-09-30 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo T cell activation by antigen-pulsed dendritic cells
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
AU1152397A (en) * 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
EP1056834A2 (en) 1998-02-20 2000-12-06 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
CA2368855C (en) 1999-04-20 2012-05-29 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Also Published As

Publication number Publication date
CA2078235C (en) 2004-01-20
AU645552B2 (en) 1994-01-20
NO923542L (no) 1992-09-11
US20030072751A1 (en) 2003-04-17
ATE124265T1 (de) 1995-07-15
NO923542D0 (no) 1992-09-11
FI105452B (fi) 2000-08-31
JPH05507905A (ja) 1993-11-11
DK0521897T3 (da) 1995-11-13
WO1991013632A1 (en) 1991-09-19
DE69110877D1 (de) 1995-08-03
DE69110877T2 (de) 1995-11-16
AU7488691A (en) 1991-10-10
EP0521897A1 (en) 1993-01-13
FI924082A (fi) 1992-09-11
JP2735947B2 (ja) 1998-04-02
FI924082A0 (fi) 1992-09-11
NO308509B1 (no) 2000-09-25
EP0521897B1 (en) 1995-06-28
CA2078235A1 (en) 1991-09-15

Similar Documents

Publication Publication Date Title
ES2074268T3 (es) Vacunacion idiotipica contra el linfoma de celulas b.
GR1000039B (el) Ενεργος ειδικη ανοσοαναστολη.
DK0669836T3 (da) Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
DK1005870T3 (da) Terapeutisk anvendelse af kimæriske antistoffer mod humant B-lymfocytdifferentieringsantigen til behandling af B-cellelymfom
ES2149768T3 (es) Conjugados de agentes enlazantes de celulas derivados de cc-1065.
ES2129423T3 (es) Vacunas.
De Gruijl UV‐induced immunosuppression in the balance
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
DK0837672T3 (da) Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme
ES2125618T3 (es) Alfa b cristalina para uso en el diagnostico y el tratamiento de enfermedades auto-inmunes y en particular la esclerosis multiple.
ES2172558T3 (es) Lubricante compatible con radiaciones para dispositivos medicos.
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.
ES2165042T3 (es) Vacuna que contiene el virus de la artritis-encefalitis de cabra y utilizacion para inmunoproteccion contra la infeccion por hiv-1.
AR019100A1 (es) Administracion de proteinas terapeuticas
DE69835615D1 (de) Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen
BR9808878A (pt) Imunização contra moléculas endógenas
AR125827A1 (es) Métodos para minimizar la neurotoxicidad asociada a la terapia con células t del receptor de antígeno quimérico (car)
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
FR1316557A (fr) Procédé de détermination de correction auditive, optimum, et appareils de prothèse établis conformément à ce procédé
ES2055164T3 (es) Preparaciones efectivas contra infecciones por pseudomonas aeruginosa asi como preparaciones que contienen inmunoglobulina-g, efectivas contra la bacteria pseudomonas aeruginosa.
Beatty et al. The cell mediated lympholysis (CML) assay as a predictor of acute graft versus host disease (AGvHD) in patients receiving marrow grafts from donors other than HLA genotypically identical siblings
UA30795A (uk) Спосіб профілактики невиношування вагітності при антифосфоліпідному синдромі
SU681928A1 (ru) Адъювант

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 521897

Country of ref document: ES